Articles from Hexagon Bio

Corteva (NYSE: CTVA), a global leader in agricultural technology, and Hexagon Bio, a biotechnology company pioneering a new way to discover nature-derived medicine, today announced a multi-million-dollar joint venture (JV) to accelerate the development of new crop protection solutions inspired by nature. The JV is the first in the agriculture sector for Hexagon Bio and the first in the pharmaceutical industry for Corteva.

Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, today announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes. Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures.